May 14, 2024Journal of Clinical Oncology

Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer

View Full Paper

Ask AI

Bookmark

Authors

FBFrancisco BautistaRadboud University Nijmegen JVJaime Verdú‐AmorósHospital Clínico Universitario de Valencia BGBirgit GeoergerInserm

Discussion

Member takes

Implication

Review examines the evolution of the clinical trial portfolio for children with cancer since 2003, highlighting efforts to expand access to novel therapies.

Key Points

Access to novel therapies for young patients depends on strategic trial portfolio expansion, addressing longstanding pediatric oncology drug development needs since 2003.
Review of the consortium portfolio assessed the historical progression of cancer clinical trials established for children and adolescents spanning from 2003 onward.
Highlights ongoing initiatives to facilitate equitable access to innovative therapies, promoting sustainable drug development pipelines in pediatric oncology care.

Cite This Study

Bautista et al. (2024) studied this question.

synapsesocial.com/papers/68e6a3aeb6db643587626df6 https://doi.org/10.1200/jco.23.01237

View Full Paper

Ask AI

Bookmark

Implication

Review examines the evolution of the clinical trial portfolio for children with cancer since 2003, highlighting efforts to expand access to novel therapies.

Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider